BridgeMD
New treatment option for Chronic Pain Syndrome
Official title Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain
ClinicalTrials.gov ID: NCT06964243
What this study is testing
- What it's testing
- Neuropathic pain is frequent and drugs relieves only 50% of the patients. Repetitive transcranial magnetic stimulation (rTMS) at high frequency (HF, usually 10Hz) applied on the primary motor cortex (M1) is an effective treatment of neuropathic pain.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- (1) existence of a definite peripheral neuropathy on both clinical and neurophysiological grounds, present for at least 6 months;
- (2) neuropathic pain clearly related to the neuropathy, as defined by a score ≥ 4/10 on the questionnaire "Douleur Neuropathique en 4 Questions"...
- (3) a score ≥ 4/10 on a 0-10 numerical rating scale (NRS) concerning the average intensity of daily ongoing pain;
- (4) age between 18 and 80 years;
- (5) affiliation with the social security system;
You likely can't join if
- (1) concomitant neurological (neurodegenerative disorders, migraine, epilepsy, stroke, tumor) or psychiatric illness;
- (2) contraindications related to TMS (intracranial ferromagnetic material);
- (3) drug-resistant or active epilepsy.
See the full eligibility criteria
- (1) existence of a definite peripheral neuropathy on both clinical and neurophysiological grounds, present for at least 6 months;
- (2) neuropathic pain clearly related to the neuropathy, as defined by a score ≥ 4/10 on the questionnaire "Douleur Neuropathique en 4 Questions" (DN4) ;
- (3) a score ≥ 4/10 on a 0-10 numerical rating scale (NRS) concerning the average intensity of daily ongoing pain;
- (4) age between 18 and 80 years;
- (5) affiliation with the social security system;
- (6) ability to provide signed informed consent.
- (1) concomitant neurological (neurodegenerative disorders, migraine, epilepsy, stroke, tumor) or psychiatric illness;
- (2) contraindications related to TMS (intracranial ferromagnetic material);
- (3) drug-resistant or active epilepsy.
The study team makes the final eligibility decision.
Where it's taking place
- Créteil, Île-de-France Region, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Créteil, Île-de-France Region, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.